From the end of April to the middle of May, Eyenovia stock has fallen day by day. Then it tried to get up but failed. Later there was an attempt that was able to help reach almost $5, but, unfortunately, it dropped. Now, stock costs $4.885 and it keeps going up.
Eyenovia, a clinical-stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print (MAP) platform technology. It announced that its exploration of VISION-1 reached the endpoint. Now, it ready to prepare for the second Phase of the third registration study, VISION-2. It will serve as the foundation for a potential FDA New Drug Application (NDA).
Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia are happy about the success of the company in studying VISION-1. The plans for VISION-2, it will prepare for FDA approval for mydriasis and for a CHAPERONE study for childhood myopia.
Editor in Chief.
Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life